Dr. Nowakowski on Evolving Treatment Paradigm of MCL

Grzegorz Nowakowski, MD, assistant professor of medicine, Mayo Clinic, discusses the evolving treatment paradigm of mantle cell lymphoma (MCL).

MCL is an area where a lot of new agents are being developed, Nowakowski explains. Moreover, what is interesting is that there is a paradigm shift from chemotherapy-based combinations to targeted therapy-based regimens in the relapsed setting. These include ibrutinib (Imbruvica) plus rituximab (Rituxan) and lenalidomide (Revlimid) and rituximab. Venetoclax (Venclexta) is another agent being explored in these regimens.

Over time, some of these more novel regimens are likely to replace chemotherapy in the relapsed setting, he adds..